119 related articles for article (PubMed ID: 37858867)
1. Switch to oral antibiotics in Gram-negative bacteraemia: a randomized, open-label, clinical trial.
Omrani AS; Abujarir SH; Ben Abid F; Shaar SH; Yilmaz M; Shaukat A; Alsamawi MS; Elgara MS; Alghazzawi MI; Shunnar KM; Zaqout A; Aldeeb YM; Alfouzan W; Almaslamani MA;
Clin Microbiol Infect; 2024 Apr; 30(4):492-498. PubMed ID: 37858867
[TBL] [Abstract][Full Text] [Related]
2. Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial.
Lee IR; Tong SYC; Davis JS; Paterson DL; Syed-Omar SF; Peck KR; Chung DR; Cooke GS; Libau EA; Rahman SBA; Gandhi MP; Shi L; Zheng S; Chaung J; Tan SY; Kalimuddin S; Archuleta S; Lye DC
Trials; 2022 Jul; 23(1):572. PubMed ID: 35854360
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.
López-Cortés LE; Delgado-Valverde M; Moreno-Mellado E; Goikoetxea Aguirre J; Guio Carrión L; Blanco Vidal MJ; López Soria LM; Pérez-Rodríguez MT; Martínez Lamas L; Arnaiz de Las Revillas F; Armiñanzas C; Ruiz de Alegría-Puig C; Jiménez Aguilar P; Del Carmen Martínez-Rubio M; Sáez-Bejar C; de Las Cuevas C; Martín-Aspas A; Galán F; Yuste JR; Leiva-León J; Bou G; Capón González P; Boix-Palop L; Xercavins-Valls M; Goenaga-Sánchez MÁ; Anza DV; Castón JJ; Rufián MR; Merino E; Rodríguez JC; Loeches B; Cuervo G; Guerra Laso JM; Plata A; Pérez Cortés S; López Mato P; Sierra Monzón JL; Rosso-Fernández C; Bravo-Ferrer JM; Retamar-Gentil P; Rodríguez-Baño J;
Lancet Infect Dis; 2024 Apr; 24(4):375-385. PubMed ID: 38215770
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.
Bhatia A; Mastim M; Shah M; Gutte R; Joshi P; Kumbhar D; Periasamy H; Palwe SR; Chavan R; Bhagwat S; Patel M; Llorens L; Friedland HD
J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM; Kornelisse RF; Hartwig NG; van der Sluijs-Bens J; van Beek RHT; van Driel A; van Rooij LGM; van Dalen-Vink I; Driessen GJA; Kenter S; von Lindern JS; Eijkemans M; Stam-Stigter GM; Qi H; van den Berg MM; Baartmans MGA; van der Meer-Kappelle LH; Meijssen CB; Norbruis OF; Heidema J; van Rossem MC; den Butter PCP; Allegaert K; Reiss IKM; Tramper-Stranders GA
Lancet Child Adolesc Health; 2022 Nov; 6(11):799-809. PubMed ID: 36088952
[TBL] [Abstract][Full Text] [Related]
7. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P
Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271
[TBL] [Abstract][Full Text] [Related]
8. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial.
von Dach E; Albrich WC; Brunel AS; Prendki V; Cuvelier C; Flury D; Gayet-Ageron A; Huttner B; Kohler P; Lemmenmeier E; McCallin S; Rossel A; Harbarth S; Kaiser L; Bochud PY; Huttner A
JAMA; 2020 Jun; 323(21):2160-2169. PubMed ID: 32484534
[TBL] [Abstract][Full Text] [Related]
9. Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia.
Tingsgård S; Bastrup Israelsen S; Jørgensen HL; Østergaard C; Benfield T
JAMA Netw Open; 2024 Jan; 7(1):e2352314. PubMed ID: 38261322
[TBL] [Abstract][Full Text] [Related]
10. Randomised, open-label, non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteraemia: the INTENSE trial protocol.
Maldonado N; Rosso-Fernández CM; Portillo-Calderón I; Borreguero Borreguero I; Tristán-Clavijo E; Palacios-Baena ZR; Salamanca E; Fernández-Cuenca F; De-Cueto M; Stolz-Larrieu E; Rodriguez-Baño J; López-Cortés LE
BMJ Open; 2023 Sep; 13(9):e075699. PubMed ID: 37673453
[TBL] [Abstract][Full Text] [Related]
11. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection.
Thurber KM; Arnold JR; Narayanan PP; Dierkhising RA; Sampathkumar P
J Glob Antimicrob Resist; 2019 Sep; 18():243-248. PubMed ID: 30926468
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
Thwaites GE; Scarborough M; Szubert A; Saramago Goncalves P; Soares M; Bostock J; Nsutebu E; Tilley R; Cunningham R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS
Health Technol Assess; 2018 Oct; 22(59):1-148. PubMed ID: 30382016
[TBL] [Abstract][Full Text] [Related]
14. Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.
Kaasch AJ; Fätkenheuer G; Prinz-Langenohl R; Paulus U; Hellmich M; Weiß V; Jung N; Rieg S; Kern WV; Seifert H;
Trials; 2015 Oct; 16():450. PubMed ID: 26452342
[TBL] [Abstract][Full Text] [Related]
15. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial.
de Jonge NA; Sikkens JJ; Zweegman S; Beeker A; Ypma P; Herbers AH; Vasmel W; de Kreuk A; Coenen JLLM; Lissenberg-Witte B; Kramer MHH; van Agtmael MA; Janssen JJWM
Lancet Haematol; 2022 Aug; 9(8):e563-e572. PubMed ID: 35691326
[TBL] [Abstract][Full Text] [Related]
16. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
18. Partial oral antibiotic treatment for bacterial brain abscess: an open-label randomized non-inferiority trial (ORAL).
Bodilsen J; Brouwer MC; van de Beek D; Tattevin P; Tong S; Naucler P; Nielsen H
Trials; 2021 Nov; 22(1):796. PubMed ID: 34772441
[TBL] [Abstract][Full Text] [Related]
19. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
20. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
